Correction to: Prostate Cancer and Prostatic Diseases 10.1038/s41391-022-00555-0, published online 03 June 2022.
In Table 4 of this article, the data in the risk of MACE and composite CV events headed receiving more than 6 months of ADT were mistakenly listed under the headed preexisting CVD, receiving more than 6 months of ADT and vice versa.
Table 4.
Subgroup analysis estimating the risk of MACE associated with GnRH antagonist comparing with GnRH agonist.
| GnRH antagonist vs GnRH agonist | MACE | Composite CV events | ||||||
|---|---|---|---|---|---|---|---|---|
| No of event | aHRa | (95% CI) | P value | No of event | aHR | (95% CI) | P value | |
| Preexisting CVD, initial staging N=1 or M=1 | ||||||||
| GnRH antagonist (n = 106) | 34 | 0.98a | (0.66–1.45) | 0.9071 | 3 | 0.16b | (0.04–0.38) | 0.013 |
| GnRH agonist (n = 1489) | 621 | 188 | ||||||
| Receiving more than 6 months of ADT (GnRH antagonist ≥6 months vs GnRH agonist ≥6 months) | ||||||||
| GnRH antagonist (n = 286) | 82 | 0.95 | (0.74–1.22) | 0.7023 | 15 | 0.30 | (0.16–0.54) | <0.0001 |
| GnRH agonist (n = 10615) | 3780 | 1637 | ||||||
| Preexisting CVD, receiving more than 6 months of ADT (GnRH antagonist ≥6 months vs GnRH agonist ≥6 months) | ||||||||
| GnRH antagonist (n = 96) | 24 | 0.64c | (0.39–1.05) | 0.0757 | 3 | 0.12d | (0.03–0.49) | 0.0032 |
| GnRH agonist (n = 2006) | 687 | 375 | ||||||
aHR adjusted hazard ratio, CV cardiovascular, GnRH gonadotropin-releasing hormone, MACE major adverse cardiovascular event (ischemic heart disease, stroke, congestive heart failure or CV-related death).
preexising CV risk: receiving cardiac therapy, diagnosis of ischemic heart diseases, stroke, or congestive heart failure 1 year before androgen deprivation therapy initiation.
aaHRs were estimated using cox model adjusted for age, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
baHRs were estimated using the Fine and Gray competing risk model adjusted for age receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
caHRs were estimated using cox model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
daHRs were estimated using the Fine and Gray competing risk model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
The original article has been corrected.
Page 4: Last sentence before the section of Survival analysis.
In patients with pre-existing CVD and receiving ADT for ≥6 months, a 70% lower risk of composite CV events was determined in GnRH antagonisttreated patients than GnRHa-treated patients (aHR 0.30; 95% CI, 0.16–0.54; p < 0.0001; Table 4).